A New Model for Funding Cost-Effectiveness Research
Patients before profits
Public Good Pharma (PGP) can reduce pharmaceutical spend by health insurers by 20% up-front and up to 90% in the future, by leveraging self-funding clinical trials. In particular, PGP conducts innovative “interventional pharmacoeconomic” (IVPE) trials to compare a low-cost therapy (e.g. repurposed generic drug) to expensive standard of care. The IVPE trials are self-funded out of the cost-savings of health insurers and designed to generate data supporting the most cost-effective therapies that can help the most patients.
Reduce Financial Toxicity
Improve Patient Outcomes
Public Good Pharma is a biotech company established as a social enterprise. We discover and design trials to clinically-validate low-cost, safe and effective therapies which have insufficient commercial incentive (e.g. repurposed generic drugs, nutraceuticals, diets, dose de-escalations and lifestyle interventions).
Unlike traditional pharma pursuing the inefficient and unsustainable “blockbuster drug” model and charging as much as the market can bear, our interests are aligned with patients and health insurers because we earn revenue from conducting self-funding IVPE trials. Our eventual goal is to seek FDA approval for these low-cost therapies, in order to maximize health equity.
We work with “payers” including self-insured employers, pass-through PBMs, state health plans and integrated health systems looking for an innovative way to manage specialty drug spend.
